PULSE BIOSCIENCES, INC. (PLSE) Form 10-Q — Aug 6, 2026
Pulse Biosciences' Q2 2026 net loss widened to $24.7 million, or $0.36 per share, from $19.2 million a year earlier, driven by a $4.9 million jump in R&D to $17.0 million as pivotal atrial fibrillation trials ramp. The company recorded its first product revenue of $434 thousand from the limited market release of the Vybrance Percutaneous Electrode System. Cash and equivalents rose to $101.6 million at June 30, 2026 from $80.7 million at year-end, after the company sold 1,919,821 shares under its February 2026 ATM for $46.8 million net, plus another 388,949 shares for $10.7 million in early July.
Key figures
- Revenue
- 434000
- Total Assets
- 115564000
- Cash Position
- 101620000
- Shares Outstanding
- 71322607
- H1 2026 revenue
- 835000
- Q2 2026 rd expense
- 16976000
- Accumulated deficit
- 506500000
- Q2 2026 sga expense
- 8457000
- Shelf 2026 capacity
- 200000000
- Af addressable market
- greater than $3.0 billion in US electrophysiology
- Catheter pivotal trial
- at least 164 evaluable patients at up to 30 sites; more than half enrolled
- August 2026 atm capacity
- 75000000
- July 2026 atm net proceeds
- 10700000
- February 2026 atm remaining
- 1000000
- Feb 2026 atm net proceeds q2
- 46800000
- First in human catheter data
- 96% procedural success of evaluable patients at one year (n=150); 96.2% for 5-second cohort (n=141); ~65 minute procedure times
- Insider atm shares purchased
- 675233
- Af us patients diagnosed annually
- approximately 1.9 million
- Cumulative warrant proceeds through jul 2026
- 65500000
Price after filing
Close on the filing date to close N calendar days later (from $38.17). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.